Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) – Analysts at William Blair boosted their Q1 2025 EPS estimates for shares of Dynavax Technologies in a research report issued on Tuesday, August 6th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of $0.04 per share for the quarter, up from their prior forecast of $0.03. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.12 per share. William Blair also issued estimates for Dynavax Technologies’ Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.10 EPS and Q4 2025 earnings at $0.03 EPS.
Dynavax Technologies (NASDAQ:DVAX – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Dynavax Technologies had a net margin of 3.91% and a return on equity of 1.52%. The firm had revenue of $73.80 million for the quarter, compared to analyst estimates of $76.92 million. During the same period last year, the firm posted $0.03 EPS.
View Our Latest Stock Report on DVAX
Dynavax Technologies Stock Performance
NASDAQ:DVAX traded up $0.40 during midday trading on Thursday, reaching $11.10. The stock had a trading volume of 2,976,587 shares, compared to its average volume of 2,151,702. The firm has a fifty day simple moving average of $11.20 and a two-hundred day simple moving average of $11.84. Dynavax Technologies has a 12-month low of $9.74 and a 12-month high of $15.15. The company has a quick ratio of 14.10, a current ratio of 15.20 and a debt-to-equity ratio of 0.36. The stock has a market cap of $1.45 billion, a P/E ratio of 185.00 and a beta of 1.28.
Insiders Place Their Bets
In other Dynavax Technologies news, Director Francis Cano sold 3,615 shares of the business’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.93, for a total transaction of $43,126.95. Following the sale, the director now directly owns 36,905 shares in the company, valued at approximately $440,276.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.98% of the company’s stock.
Institutional Investors Weigh In On Dynavax Technologies
Institutional investors and hedge funds have recently made changes to their positions in the business. Duality Advisers LP purchased a new stake in shares of Dynavax Technologies in the 1st quarter worth about $227,000. Natixis Advisors L.P. boosted its position in shares of Dynavax Technologies by 10.5% in the 4th quarter. Natixis Advisors L.P. now owns 19,058 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 1,804 shares in the last quarter. Executive Wealth Management LLC purchased a new stake in shares of Dynavax Technologies in the 4th quarter worth about $280,000. Boston Partners purchased a new stake in shares of Dynavax Technologies in the 1st quarter worth about $292,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Dynavax Technologies by 67.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,099 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 10,143 shares in the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.
About Dynavax Technologies
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Recommended Stories
- Five stocks we like better than Dynavax Technologies
- Consumer Discretionary Stocks Explained
- MarketBeat Week in Review – 8/5 – 8/9
- How to Effectively Use the MarketBeat Ratings Screener
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- What is the Hang Seng index?
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.